Hemoglobin variability does not predict mortality in European hemodialysis patients.
Patients with CKD exhibit significant within-patient hemoglobin (Hb) level variability, especially with the use of erythropoiesis stimulating agents (ESAs) and iron. Analyses of dialysis cohorts in the United States produced conflicting results regarding the association of Hb variability with patient outcomes. Here, we determined Hb variability in 5037 European hemodialysis (HD) patients treated over 2 years to identify predictors of high variability and to evaluate its association with all-cause and cardiovascular disease (CVD) mortality. We assessed Hb variability with various methods using SD, residual SD, time-in-target (11.0 to 12.5 g/dl), fluctuation across thresholds, and area under the curve (AUC). Hb variability was significantly greater among incident patients than prevalent patients. Compared with previously described cohorts in the United States, residual SD was similar but fluctuations above target were less frequent. Using logistic regression, age, body mass index, CVD history, dialysis vintage, serum albumin, Hb, angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) use, ESA use, dialysis access type, dialysis access change, and hospitalizations were significant predictors of high variability. Multivariable adjusted Cox regression showed that SD, residual SD, time-in-target, and AUC did not predict all-cause or CVD mortality during a median follow-up of 12.4 months (IQR: 7.7 to 17.4). However, patients with consistently low levels of Hb (<11 g/dl) and those who fluctuated between the target range and <11 g/dl had increased risks for death (RR 2.34; 95% CI: 1.24 to 4.41 and RR 1.74; 95% CI: 1.00 to 3.04, respectively). In conclusion, although Hb variability is common in European HD patients, it does not independently predict mortality.
Eckardt
Kai-Uwe
KU
Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Erlangen, Germany. Kai-Uwe.Eckardt@uk-erlangen.de
Kim
Joseph
J
Kronenberg
Florian
F
Aljama
Pedro
P
Anker
Stefan D
SD
Canaud
Bernard
B
Molemans
Bart
B
Stenvinkel
Peter
P
Schernthaner
Guntram
G
Ireland
Elizabeth
E
Fouqueray
Bruno
B
Macdougall
Iain C
IC
D000368:Aged; D005060:Europe / Q000453:epidemiology; D005260:Female; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D006454:Hemoglobins
Clin J Am Soc Nephrol. 2008 Nov;3(6):1733-40
18922985
Clin J Am Soc Nephrol. 2008 May;3(3):777-82
18337553
Nephrol Dial Transplant. 2004 May;19 Suppl 2:ii1-47
15206425
Nephrol Dial Transplant. 2009 May;24(5):1378-83
19196826
Clin J Am Soc Nephrol. 2008 Jan;3(1):133-8
18045862
Nephrol Dial Transplant. 2007 Aug;22(8):2129-32
17595177
Am J Kidney Dis. 1990 May;15(5):458-82
2333868
N Engl J Med. 1998 Aug 27;339(9):584-90
9718377
N Engl J Med. 2009 Nov 19;361(21):2019-32
19880844
Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154
17276798
Nephron Clin Pract. 2008;108(1):c67-74
18182782
Nephrol Dial Transplant. 2007 Jan;22(1):187-95
16998216
N Engl J Med. 2006 Nov 16;355(20):2085-98
17108343
Am J Kidney Dis. 2004 Jul;44(1):94-111
15211443
Nephrol Dial Transplant. 2010 Aug;25(8):2715-22
20190241
Clin J Am Soc Nephrol. 2009 Jul;4(7):1176-82
19423567
Kidney Int. 2007 Sep;72(6):671-5
17597701
Kidney Int. 2003 Oct;64(4):1514-21
12969173
J Am Soc Nephrol. 2007 Dec;18(12):3164-70
18003781
J Am Soc Nephrol. 2009 Mar;20(3):479-87
19211716
N Engl J Med. 2006 Nov 16;355(20):2071-84
17108342
Clin J Am Soc Nephrol. 2006 Nov;1(6):1205-10
17699349